NBY  Novabay Pharmaceuticals Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.0097 (-1.6441%)

Stability Price

Overvalued by 49.13%

Company Metrics

  • 0 P/E
  • 27.6893 P/S
  • 16.8571 P/B
  • -0.321 EPS
  • -2,078.99% Cash ROIC
  • 1.62 Cash Ratio
  • 0 / 0% Dividend
  • 362,598.00 Avg. Vol.
  • 35.51M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Company Shares of NovaBay Pharmaceuticals, Inc. Drops by -3.92%
News Watch International - 13 hours ago
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has lost 3.92% during the past week and dropped 10.74% in the last 4 weeks.
Morning Buzz: Alibaba Group Holding Ltd (NYSE:BABA), NovaBay Pharmaceuticals ...
Stock Transcript - 15 hours ago
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), announced that it will report second quarter financial results after market close on Thursday, August 13.
Company Shares of NovaBay Pharmaceuticals, Inc. Drops by -7.79%
American Trade Journal - Jul 27, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has lost 7.79% during the past week and dropped 8.32% in the last 4 weeks.
Maxim Group Remains Positive on Novabay Pharmaceuticals, Inc. (NBY) In Light ...
Smarter Analyst - Jun 5, 2015
A research report was issued today by Maxim Group analyst Jason Kolbert on Novabay Pharmaceuticals, Inc. (NYSE:NBY), after the company announced receipt of 510(k) clearance from the U.S.
NovaBay Pharmaceuticals to Hold Second Quarter 2015 Conference Call on August 13
Business Wire (press release) - Jul 30, 2015
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that it ...
NovaBay Pharmaceuticals Inc.: NovaBay Pharmaceuticals to Hold Second Quarter ... - The Wall Street Transcript
Maxim Rates NovaBay At Buy, Says 'The Eyes Have It!'
Benzinga - Apr 30, 2015
In a report published Thursday, analysts at Maxim Group initiated coverage of NovaBay Pharmaceuticals, Inc. (NYSE: NBY) with a Buy rating and a price target of $2.
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) Short Interest Update
American Trade Journal - Jul 29, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has seen a shortfall of 102,798 shares or 3.8% in the short interest. The remaining shorts are 5.5% of the total floated shares.
NovaBay Pharmaceuticals Short Interest Down 3.8% in July (NBY) - Mideast Time
NovaBay Pharmaceuticals Sees Large Drop in Short Interest (NBY)
Dakota Financial News - Jul 28, 2015
Approximately 5.5% of the shares of the company are short sold. Based on an average daily volume of 162,065 shares, the short-interest ratio is currently 16.1 days.
Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System
TheStreet.com - Jun 4, 2015
NEW YORK (TheStreet) -- Novabay Pharmaceuticals (NBY - Get Report) shares are up 11.46% to 93 cents per share in afternoon trading on Thursday after the biopharmaceutical company announced that it received clearance from the Food and Drug ...
FDA Clears NovaBay Pharmaceuticals' New High-Tech Device, intelli-Case, for ... - MarketWatch
Maxim Weighs in on Biotech Stocks: StemCells Inc (STEM), NovaBay ...
Smarter Analyst - May 15, 2015
Jason Kolbert of Maxim Group rates stocks in the biotechnology sector and he's ranked #2811 out of 3602 analysts on TipRanks. Yesterday, Kolbert made two news ratings for StemCells Inc (NASDAQ:STEM) and NovaBay Pharmaceuticals, Inc.